Opthea (ASX:OPT) EBIT per Share : A$-0.47 (TTM As of Jun. 2024)

View and export this data going back to 1991. Start your Free Trial

What is Opthea EBIT per Share?

Opthea's EBIT per Share for the six months ended in Jun. 2024 was A$-0.26. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 was A$-0.47.

During the past 3 years, the average EBIT per Share Growth Rate was -47.90% per year. During the past 5 years, the average EBIT per Share Growth Rate was -42.20% per year. During the past 10 years, the average EBIT per Share Growth Rate was -22.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Opthea's EBIT per Share or its related term are showing as below:

ASX:OPT' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -87.9 Med: -21.6 Max: 29.2
Current: -47.9

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Opthea was 29.20% per year. The lowest was -87.90% per year. And the median was -21.60% per year.

ASX:OPT's 3-Year EBIT Growth Rate is ranked worse than
88.72% of 1250 companies
in the Biotechnology industry
Industry Median: 2.8 vs ASX:OPT: -47.90

Opthea's EBIT for the six months ended in Jun. 2024 was A$-163.65 Mil.

Opthea EBIT per Share Historical Data

The historical data trend for Opthea's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opthea EBIT per Share Chart

Opthea Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

EBIT per Share

Get a 7-Day Free Trial

-0.08

-0.18

-0.40

-0.45

-0.47

Opthea Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBIT per Share	Get a 7-Day Free Trial															-0.28	-0.22	-0.23	-0.21	-0.26

Opthea EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Opthea's EBIT per Share for the fiscal year that ended in Jun. 2024 is calculated as

	EBIT per Share		(A: Jun. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-300.283	/	638.203
=	-0.47

Opthea's EBIT per Share for the quarter that ended in Jun. 2024 is calculated as

	EBIT per Share		(Q: Jun. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-163.653	/	632.970
=	-0.26

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.47

Opthea (ASX:OPT) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Opthea EBIT per Share Related Terms

Thank you for viewing the detailed overview of Opthea's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Opthea Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (ASX:OPT) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

CKDXF:USA OPT:USA UKJ:Germany

Address

650 Chapel Street, Level 4, Suite 0403, South Yarra, VIC, AUS, 3141

Website

https://www.opthea.com

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.